id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-301454-ayf42grs	Phyu Khin, Phyu	A potential therapeutic combination for treatment of COVID-19: synergistic effect of DPP4 and RAAS suppression	2020-08-14		.txt	text/plain	1762	105	45	A recent study proved that coronavirus SARS-CoV-2 also uses dipeptidyl peptidase-4 (DPP4, also known as adenosine deaminase complexing protein 2, CD26) as a co-receptor when entering cells. In particular, SARS-CoV-2 is able to infect T lymphocytes despite their very low expression level of ACE-2, implying an alternate receptor for viral entry [5, 6] . Among elderly patients (average age: 80 years) infected with SARS-CoV-2 in Italy in early 2020, the mortality rate was highest in patients with hypertension (69%), followed by those with type 2 diabetes (31%), and those with ischemic heart diseases (27%) [5] . The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor-and angiotensin II receptor blocker-based cardiovascular therapies. Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China	./cache/cord-301454-ayf42grs.txt	./txt/cord-301454-ayf42grs.txt